Emerging therapies for urothelial cancer

César Serrano; Rafael Morales; Cristina Suárez; Isaac Núñez; Claudia Valverde; Jordi Rodón; Jordi Humbert; Olga Padrós; Joan Carles

doi:10.1016/j.ctrv.2011.10.007

Emerging therapies for urothelial cancer

César Serrano, Rafael Morales, Cristina Suárez, Isaac Núñez, Claudia Valverde, Jordi Rodón, Jordi Humbert, Olga Padrós, Joan Carles

Departament de Medicina

Producció científica: Contribució a revista › Article de revisió › Recerca › Avaluat per experts

9 Cites (Scopus)

Resum

Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1. year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials. © 2011 Elsevier Ltd.

Idioma original	Anglès
Pàgines (de-a)	311-317
Revista	Cancer Treatment Reviews
Volum	38
Número	4
DOIs	https://doi.org/10.1016/j.ctrv.2011.10.007
Estat de la publicació	Publicada - 1 de juny 2012

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1016/j.ctrv.2011.10.007

Com citar-ho

@article{824de5a36c8c46e0bf7a9becaca28af1,

title = "Emerging therapies for urothelial cancer",

abstract = "Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1. year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials. {\textcopyright} 2011 Elsevier Ltd.",

keywords = "Anti-EGFR, Bladder cancer, Emerging treatments, Eribulin, MTOR inhibition, Nab-paclitaxel, PARP, Sorafenib, Sunitinib, Volasertib",

author = "C{\'e}sar Serrano and Rafael Morales and Cristina Su{\'a}rez and Isaac N{\'u}{\~n}ez and Claudia Valverde and Jordi Rod{\'o}n and Jordi Humbert and Olga Padr{\'o}s and Joan Carles",

year = "2012",

month = jun,

day = "1",

doi = "10.1016/j.ctrv.2011.10.007",

language = "English",

volume = "38",

pages = "311--317",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Emerging therapies for urothelial cancer

AU - Serrano, César

AU - Morales, Rafael

AU - Suárez, Cristina

AU - Núñez, Isaac

AU - Valverde, Claudia

AU - Rodón, Jordi

AU - Humbert, Jordi

AU - Padrós, Olga

AU - Carles, Joan

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1. year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials. © 2011 Elsevier Ltd.

AB - Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1. year. Most second-line chemotherapeutic agents tested have been disappointing. Thus, new treatment strategies are clearly needed. This review focuses on emerging therapies in urothelial carcinoma. Results from recent clinical trials, investigating the activity of new generation cytostatic agents, as well as results from studies assessing the toxicity and efficacy of novel targeted therapies, are discussed. In this setting, anti-epidermal growth factor receptor, angiogenesis, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors account for the majority of phase I and II trials. © 2011 Elsevier Ltd.

KW - Anti-EGFR

KW - Bladder cancer

KW - Emerging treatments

KW - Eribulin

KW - MTOR inhibition

KW - Nab-paclitaxel

KW - PARP

KW - Sorafenib

KW - Sunitinib

KW - Volasertib

U2 - 10.1016/j.ctrv.2011.10.007

DO - 10.1016/j.ctrv.2011.10.007

M3 - Review article

SN - 0305-7372

VL - 38

SP - 311

EP - 317

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

IS - 4

ER -

Emerging therapies for urothelial cancer

Resum

SDG de les Nacions Unides

Accés al document

Fingerprint

Com citar-ho